Nurix Therapeutics, Inc. (NRIX)
| Market Cap | 1.77B |
| Revenue (ttm) | 71.78M |
| Net Income (ttm) | -295.28M |
| Shares Out | 103.41M |
| EPS (ttm) | -3.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,116,173 |
| Open | 16.63 |
| Previous Close | 16.49 |
| Day's Range | 16.63 - 17.47 |
| 52-Week Range | 8.20 - 22.50 |
| Beta | 1.98 |
| Analysts | Strong Buy |
| Price Target | 30.50 (+78.68%) |
| Earnings Date | Apr 8, 2026 |
About NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical tr... [Read more]
Financial Performance
In fiscal year 2025, Nurix Therapeutics's revenue was $83.98 million, an increase of 53.95% compared to the previous year's $54.55 million. Losses were -$264.46 million, 36.6% more than in 2024.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price target is $30.5, which is an increase of 78.68% from the latest price.
News
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand ther...
Nurix Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Lead BTK degrader is advancing to phase III for CLL, showing strong efficacy and safety, with a new confirmatory trial against pirtobrutinib. Autoimmune and early-stage programs are progressing, and the company is well-funded with $650M in cash.
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)
Nurix Therapeutics to Participate in Upcoming Investor Conference
BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Nurix Therapeutics Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium
Degrader therapies in immunology offer advantages over inhibitors by eliminating entire protein functions, enabling targeting of challenging proteins like STAT6. Key programs, including STAT6 (with Sanofi), BTK, and IRAK4 (with Gilead), are advancing, with major clinical milestones expected this year.
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile i...
Nurix Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Bexobrutideg achieved strong clinical results in CLL, with an 83% response rate and 22.1 months PFS, supporting pivotal and head-to-head phase III trials. The pipeline expands into autoimmune and CNS diseases, with robust financials and industry enthusiasm for the degrader class.
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymph...
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of t...
Nurix Therapeutics Transcript: Study Update
Bexobrutideg demonstrated an 83% response rate and 22-month median PFS in heavily pretreated CLL, including those with CNS involvement and high-risk mutations, with a favorable safety profile. Waldenstrom's patients showed 75–83% response rates. The pivotal DAYBreak program is underway, with combination and front-line studies planned.
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median du...
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested
Nurix Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing a pipeline of targeted protein degraders, with Bexovibart leading in CLL and autoimmune indications. Upcoming pivotal studies and ASH presentations will highlight efficacy, safety, and dose selection. Collaborations with Sanofi and Gilead expand the pipeline into STAT6 and IRAK-4 programs.
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
SAN FRANCISCO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...
Nurix Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Long-term data on BTK degraders will be presented at ASH, with pivotal CLL trials advancing and a strong focus on triple-exposed patients. Platform expansion into autoimmune diseases and robust partnerships with Gilead and Sanofi are underway, supported by over $650 million in cash.
Nurix Therapeutics Transcript: Stifel 2025 Healthcare Conference
Targeted protein degradation is advancing in CLL with pivotal trials for Bexdeg, which shows high efficacy and selectivity. The pipeline includes inflammation and oncology programs, with strong financial backing and key data updates expected at ASH and in 2026.
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board's research, drug development and commercialization expertise Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board's researc...
Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies to treat cancer an...
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of tar...
Nurix Therapeutics Transcript: Study Update
Pivotal phase II trial for Bexobrutideg in relapsed/refractory CLL has begun, with a 600 mg dose selected for registrational studies based on strong efficacy, safety, and broad mutational coverage. Pipeline programs in STAT6 and IRAK4 degraders are advancing, and the company is well-funded through 2028.
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...